A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Exelixis, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 60,098 shares of EXEL stock, worth $2.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,098
Previous 60,098 -0.0%
Holding current value
$2.07 Million
Previous $1.56 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$21.96 - $27.6 $33,071 - $41,565
-1,506 Reduced 2.44%
60,098 $1.56 Million
Q2 2024

Jul 29, 2024

BUY
$20.34 - $23.73 $27,743 - $32,367
1,364 Added 2.26%
61,604 $1.38 Million
Q4 2023

Jan 30, 2024

BUY
$19.25 - $24.13 $96,134 - $120,505
4,994 Added 9.04%
60,240 $1.45 Million
Q3 2023

Oct 25, 2023

BUY
$19.04 - $22.74 $61,708 - $73,700
3,241 Added 6.23%
55,246 $1.21 Million
Q2 2023

Aug 07, 2023

BUY
$18.17 - $20.48 $78,803 - $88,821
4,337 Added 9.1%
52,005 $993,000
Q1 2023

May 08, 2023

BUY
$16.3 - $19.41 $31,850 - $37,927
1,954 Added 4.27%
47,668 $925,000
Q4 2022

Feb 01, 2023

BUY
$14.96 - $17.39 $43,787 - $50,900
2,927 Added 6.84%
45,714 $733,000
Q3 2022

Nov 09, 2022

BUY
$15.68 - $22.27 $36,895 - $52,401
2,353 Added 5.82%
42,787 $671,000
Q2 2022

Aug 09, 2022

SELL
$17.44 - $23.16 $39,466 - $52,411
-2,263 Reduced 5.3%
40,434 $842,000
Q1 2022

Apr 21, 2022

SELL
$17.03 - $22.67 $16,042 - $21,355
-942 Reduced 2.16%
42,697 $968,000
Q4 2021

Feb 01, 2022

BUY
$15.84 - $21.88 $163,579 - $225,954
10,327 Added 31.0%
43,639 $798,000
Q3 2021

Nov 15, 2021

BUY
$16.3 - $21.14 $14,604 - $18,941
896 Added 2.76%
33,312 $704,000
Q2 2021

Jul 30, 2021

SELL
$17.95 - $25.56 $33,153 - $47,209
-1,847 Reduced 5.39%
32,416 $591,000
Q1 2021

May 03, 2021

SELL
$20.53 - $25.22 $70,541 - $86,655
-3,436 Reduced 9.11%
34,263 $774,000
Q4 2020

Jan 28, 2021

BUY
$18.39 - $24.8 $68,134 - $91,884
3,705 Added 10.9%
37,699 $757,000
Q2 2020

Jul 28, 2020

BUY
$16.46 - $27.42 $118,676 - $197,698
7,210 Added 26.92%
33,994 $807,000
Q1 2020

May 06, 2020

BUY
$14.46 - $21.8 $90,938 - $137,100
6,289 Added 30.69%
26,784 $461,000
Q4 2019

Jan 21, 2020

BUY
$15.15 - $18.89 $18,725 - $23,348
1,236 Added 6.42%
20,495 $361,000
Q3 2019

Oct 18, 2019

BUY
$17.68 - $22.65 $18,899 - $24,212
1,069 Added 5.88%
19,259 $341,000
Q2 2019

Jul 30, 2019

SELL
$18.93 - $24.75 $46,416 - $60,687
-2,452 Reduced 11.88%
18,190 $389,000
Q1 2019

Apr 29, 2019

SELL
$19.6 - $24.76 $65,934 - $83,292
-3,364 Reduced 14.01%
20,642 $491,000
Q4 2018

Jan 25, 2019

BUY
$13.65 - $21.8 $20,434 - $32,634
1,497 Added 6.65%
24,006 $472,000
Q3 2018

Nov 09, 2018

BUY
$15.87 - $22.4 $24,566 - $34,675
1,548 Added 7.39%
22,509 $399,000
Q1 2018

May 03, 2018

SELL
$22.15 - $31.89 $1,284 - $1,849
-58 Reduced 0.28%
20,961 $464,000
Q4 2017

Jan 31, 2018

BUY
$24.23 - $30.93 $116,788 - $149,082
4,820 Added 29.75%
21,019 $639,000
Q3 2017

Nov 08, 2017

BUY
$23.35 - $29.24 $378,246 - $473,658
16,199
16,199 $393,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.1B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.